What is Helix?
Helix operates at the nexus of clinical care, research, and genomics, offering an end-to-end platform designed for health systems, life sciences companies, and payers. The company's proprietary Exome+ assay and one of the world's largest CLIA/CAP next-generation sequencing labs enable comprehensive population genomics initiatives. Helix supports various aspects of this field, including patient recruitment and engagement, clinically actionable disease screening, return of genomic results, and both basic and translational research. Its mission is to accelerate the integration of genomic data into everyday healthcare, making personalized medicine more accessible and actionable.
How much funding has Helix raised?
Helix has raised a total of $383M across 4 funding rounds:
Series A
$100M
Series B
$200M
Grant
$33M
Series C
$50M
Series A (2015): $100M with participation from Illumina, Warburg Pincus, and Sutter Hill Ventures
Series B (2018): $200M led by Draper Fisher Jurvetson (DFJ), Illumina, Kleiner Perkins Caufield & Byers, Mayo Clinic, Sutter Hill Ventures, and Warburg Pincus
Grant (2020): $33M supported by U.S. National Institutes of Health (NIH)
Series C (2021): $50M featuring DFJ Growth, Warburg Pincus, Temasek, Mayo Clinic, and Kleiner Perkins
Key Investors in Helix
DFJ Growth
DFJ Growth is a late-stage global venture capital firm that provides capital to companies in seed, early, and growth-stages, focusing on rapidly scaling technology companies poised for market leadership.
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing, supporting investors and management teams in building long-term, sustainable success across diverse market cycles.
Temasek
Temasek is a global investment company headquartered in Singapore, operating as a generational investor focused on making a difference with tomorrow in mind.
What's next for Helix?
With its recent major strategic investment, Helix is poised for accelerated growth and innovation. The substantial capital infusion is expected to fuel the expansion of its platform capabilities, enhance its research and development efforts, and broaden its market penetration. This strategic backing will likely enable Helix to further solidify its position as a leader in population genomics, driving advancements in disease screening, personalized treatment strategies, and the overall utility of genomic information in clinical decision-making. The company's trajectory suggests a continued focus on partnerships and technological development to unlock the full potential of genomic data for improved health outcomes.
See full Helix company page
